These authors describe a common DNA variant in the promoter sequence of the SPP1 gene, encoding osteopontin, which affects both disease severity and response to corticosteroids. 5 The authors used informatics approaches, based on their earlier studies in normal subjects and from comparisons of rapid vs slow progression in DMD, to select a limited set of 29 candidate polymorphisms for analysis. One of the polymorphisms is a previously known single base variant in the promoter region of SPP1, and the authors provide evidence that the G allele of rs28357094 (observed in 35% of cases) is associated with more severe disease, as measured by either time to continuous wheelchair use or grip strength in 2 independent cohorts. The severe allele is present in about a third of all people, so this single allele could account for a substantial portion of the variability in disease progression. This study has important implications, but also limitations. One implication of this work is that presence of the G allele may provide a basis for stratifying patients entering clinical trials according to the anticipated rate of disease progression. This may improve the power of the trial by reducing interindividual heterogeneity, thereby permitting clinicians to select the relatively rapidly progressing subjects who may respond better to therapy. This exciting result needs to be replicated in larger numbers of boys with DMD, as the total sample size tested by Pegoraro et al. was small by genetic association standards: the joint p value of the whole study was ϳ0.001, whereas convincing association evidence requires a p value less than ϳ10 Ϫ7 . Furthermore, the true effect on disease progression cannot be measured accurately from the same data used to discover variant association as the discovery of genetic associations often overstates the effect size. Thus, the magnitude of effect of the G allele is yet to be established. The large calculated increase in the rate of progression in subjects who carry the rarer G allele compared to those with the common allele is surprising, given the relatively modest decrement of 1 year of remaining ambulatory attributed to the G allele. It is also surprising that the authors successfully identified this genotype given that both the CINRG (75%) and Padova (55%) cohorts varied in corticosteroid use and doubtless other variables (for example, obesity, supportive treatments). It is unlikely that variants in SPP1 account for all observed variations in DMD disease severity. Thus, there is still a need for thorough genome-wide searches for common and rare DNA variants that modify the course of DMD. Such a search is now possible with new, inexpensive, and comprehensive sequencing of individual human genomes. An example of such a genetic modifier identified from a genome-wide screen is the recent identification of variants in IFRD1 that modify lung disease in cystic fibrosis. 6 These comprehensive genomic explorations can point to new therapeutic targets and provide novel insights into disease pathogenesis, even though the effect of a given allele is frequently small. In DMD, the SPP1 variants associated with disease severity suggest that osteopontin is a rational therapeutic target. Osteopontin is a cytokine that promotes immune cell migration and survival; high tissue and circulating levels of osteopontin have been identified in a variety of muscular dystrophies, various inflammatory disorders, and cancer. A recent study by Vetrone et al. 7 has implicated osteopontin modulation as a relevant therapeutic strategy because knockout of osteopontin lessened disease severity and muscle fibrosis in the mdx mouse. Thus, many additional therapeutic leads could be unearthed by genome-wide explorations. An interesting note that begs further inquiry is the finding by Vetrone et al. 7 that suppression of osteopontin lessens fibrosis (and disease severity) in mdx mice. Paradoxically, it is the G allele, associated with low osteopontin expression in mice, which is associated with more severe disease in humans. If the results of the present study 5 are confirmed, the authors will have found a genotype deserving study in many of the muscular dystrophies and neuromuscular diseases; moreover, a new target for treatment may have been identified. This pioneering study in DMD is a harbinger of what will become an integral part of the care of patients with diseases caused by single or multiple genetic abnormalities. Full understanding of determinants of disease severity and of responses to treatment could ultimately revolutionize not only clinical trials but the specific treatment of each patient.
